The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of X-82 in Patients With Advanced Solid Tumors
Official Title: Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors
Study ID: NCT01296581
Brief Summary: The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Name: Gina Courtney, MD
Affiliation: Study PI
Role: PRINCIPAL_INVESTIGATOR